Эффективность и переносимость препарата лакосамид (Вимпат) в лечении эпилепсии у взрослых (обзор литературы)
https://doi.org/10.17650/2073-8803-2014-9-4-59-68
Аннотация
Об авторах
О. А. Пылаева
ООО «Институт детской неврологии и эпилепсии им. Святителя Луки», Россия, 143396, Москва, Троицк, п. Пучково, ул. Светлая, 6
Россия
Россия
К. Ю. Мухин
ООО «Институт детской неврологии и эпилепсии им. Святителя Луки», Россия, 143396, Москва, Троицк, п. Пучково, ул. Светлая, 6
Россия
Россия
М. Б. Миронов
ООО «Институт детской неврологии и эпилепсии им. Святителя Луки», Россия, 143396, Москва, Троицк, п. Пучково, ул. Светлая, 6
Россия
Россия
Список литературы
1. Артемова И.Ю., Бадалян О.Л., Богомазова М.Л. и др. Опыт применения лакосамида при различных формах эпилепсии (результаты наблюдательного исследования в учреждениях амбулаторной сети городского здравоохранения г. Москвы. Эпилепсия и пароксизмальные состояния 2011;3(3):15–20. [Artyomova I.Yu., Badalyan O.L., Bogomazova M.L. et al. Experience of application of lacosamide with various forms of epilepsy (results of observation study in out-patient institutions of Municipal Health-Care Network of Moscow. Epilepsy and Paroxysmal States 2011;3(3):15–20].
2. Воронкова К.В., Пылаева О.А., Федин А.И. Современные принципы лечения фокальных эпилепсий. Эпилепсия 2011;4(1):2–14. [Voronkova K.V., Pylaeva O.A., Fedin A.I. Modern principles of treatment of focal epilepsies. Epilepsy 2011;4(1):2–14].
3. Зенков Л.Р. Противоэпилептический препарат лакосамид (вимпат). Журнал неврологии и психиатрии им. С.С. Корсакова 2010;110(10):72–9. [Zenkov L.R. Antiepileptic drug lacosamide (vimpat). S.S. Korsakov Journal of Neurology and Psychiatrics 2010;110(10):72–9].
4. Мильчакова Л.Е., Гехт А.Б. Эффективность и безопасность нового противоэпилептического препарата лакосамид у больных фокальной эпилепсией (данные двойных слепых плацебоонтролируемых исследований). Журнал неврологии и психиатрии им. С.С. Корсакова 2010;110(3 выпуск 2):39–43. [Milchakova L.E., Gekht A.B. Efficacy and safety of the new antiepileptic drug lacosamide for patients with focal epilepsy (data of double blind placebo controlled studies). S.S. Korsakov Journal of Neurology and Psychiatrics 2010;110(3 issue 2):39–43].
5. Миронов М.Б., Мухин К.Ю., Пылаева О.А. Эффективность вимпата (лакосамид) у пациентки с резистентной формой криптогенной фокальной эпилепсии с фокальными аутомоторными и вторично-генерализованными судорожными приступами (описание случая). Русский журнал детской неврологии 2012;8(2):3–12. [Mironov M.B., Mukhin K.Yu., Pylaeva O.A. Efficacy of vimpat (lacosamide) in a patient with resistant form of cryptogenic focal epilepsy with focal automotoric and secondarily generalized seizures (case report). Russian Journal of Child Neurology 2012;8(2):3–12].
6. Мухин К.Ю., Петрухин А.С., Миронов М.Б. Эпилептические синдромы Диагностика и терапия (справочное руководство). М.: Системные решения, 2008. 224 с. [Mukhin K.Yu., Petrukhin A.S., Mironov M.B. Epileptic syndromes. Diagnostics and therapy (handbook). Moscow: Systemnye Resheniya, 2008. 224 .].
7. Мухин К.Ю., Тысячина М.Д., Глухова Л.Ю., Фрейдкова Н.В. Клинический случай применения лакосамида (вимпат) в лечении резистентной формы симптоматической фокальной эпилепсии. Русский журнал детской неврологии 2011;6(2):37–42. [Mukhin K.Yu., Tysyachina M.D., Glukhova L.Yu.,
8. Freidkova N.V. Clinical case of application of lacosamide (vimpat) for treatment of resistant form of symptomatic focal epilepsy. Russian Journal of Child Neurology 2011;6(2):37–42].
9. Петрухин А.С., Воронкова К.В., Пылаева О.А. Лакосамид в лечении эпилепсии. Журнал неврологии и психиатрии им. С.С. Корсакова 2012;112(6 выпуск 2): 65–71. [Petrukhin A.S., Voronkova K.V., Pylaeva O.A. Lacosamide for treatment of epilepsy. S.S. Korsakov Journal of Neurology and Psychiatrics 2012;112(6 issue 2):65–71].
10. Becerra J.L., Ojeda J., Corredera E., Ruiz Gimenez J. Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide. CNS Drugs 2011;25 Suppl 1:3–16.
11. Benhaddi H., Gunn A., Ferro B. Medicoeconomic evaluation of lacosamide adjunctive therapy in the treatment of patients with refractory epilepsy in Scotland and Spain.13th Annual European Congress: health technology assessment, 6–9 November 2010, Prague. 11. Ben-Menachem E. Lacosamide: an nvestigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc) 2008;44(1):35–40.
12. Ben-Menachem E. The adjuvant treatment of partial seizures in epilepsy: focus on lacosamide. Foreword. CNS Drugs 2011; 25 Suppl 1:1–2.
13. Ben-Menachem E., Biton V., Jatuzis D. et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48(7):1308–17.
14. Biton V. Lacosamide for the treatment of partial-onset seizures. Expert Rev Neurother 2012;12(6):645–55.
15. Biton V., Rosenfeld W.E., Whitesides J. et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partialonset seizures. Epilepsia 2008;49(3):418–24.
16. Bolin K., Berggren F., Forsgren L. Lacosamide as treatment of epileptic seizures – cost utility results for Sweden. Acta Neurol Scand 2010;121(6):406–12.
17. Borghs S., de la Loge C., Cramer J.A. Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. Epilepsy Behav 2012;23(3):230–4.
18. Cawello W., Boekens H., Bonn R. Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet 2012;37(4):241–8.
19. Chatzistefanidis D., Karvouni E., Kyritsis A.P., Markoula S. First case of lacosamide-induced psychosis. Clin Neuropharmacol 2013;36(1):27–8.
20. Chinnasami S., Rathore C., Duncan J.S. Sinus node dysfunction: An adverse effect of lacosamide. Epilepsia 2013;54(6):е90–3. doi: 10.1111/epi.12108.
21. Chung S., Ben-Menachem E., Sperling M.R. et аl. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs 2010;24(12):1041–54.
22. Chung S., Sperling M.R., Biton V. et al.; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51(6):958–67.
23. Elger C.E., Schmidt D. Modern management of epilepsy: а practical approach. Epilepsy Behav 2008;12(4):501–39.
24. Errington A.C., Coyne L., Stohr T. et al. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006;50(8):1016–29.
25. Errington A.C., Stöhr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73(1): 157–69.
26. Flores L., Kemp S., Colbeck K. et al. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK). Seizure 2012;21(7):512–7.
27. Garcia-Morales I., Delgado R.T., Falip M. et al. Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures. Seizure 2011;20(10):801–4.
28. Gil-Nagel A., Marin H. Lacosamide: a new generation in the treatment of epilepsy. Rev Neurol 2011;52(3):159–62.
29. Glauser T., Ben-Menachem E., Bourgeois B. et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094–120.
30. Guilhoto L.M., Loddenkemper T., Gooty V.D. et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 2011;44(6):414–9.
31. Halasz P., Kalviainen R., Mazurkiewicz-Beldzinska M. et al.; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50(3):443–53.
32. Hao X.T., Wong I.S., Kwan P. Interrater reliability of the international consensus definition of drug-resistant epilepsy: a pilot study. Epilepsy Behav 2011;22(2):388–90.
33. Harden C.L., Cohn A., Lowe M., Serrano E. Initial post marketing experience with lacosamide in adult patients with epilepsy. Epilepsy Res 2012;98(2–3):260–3.
34. Harris J.A., Murphy J.A. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain. Ann Pharmacother 2009;43(11):1809–17.
35. Harris J.A., Murphy J.A. Lacosamide and еpilepsy. CNS Neurosci Ther 2011;17(6):678–82.
36. Helmstaedter C., Witt J.A. The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepsy Behav 2013;26(2):182–7.
37. Höfler J., Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia 2013;54(3):393–404.
38. Husain A., Chung S., Faught E. et al. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia 2012;53(3):521–8.
39. Johannessen S.I., Ben-Menachem E. Management of focal-onset seizures. an update on drug treatment. Drugs 2006;66(13): 1701–25.
40. Jones G.L., Popli G.S., Silvia M.T. Lacosamide-induced valproic acid toxicity. Pediatr Neurol 2013;48(4):308–10.
41. Kamel J.T., Degruyter M.A., D'Souza W.J., Cook M.J. Clinical experience with using lacosamide for the treatment of epilepsy in a tertiary centre. Acta Neurol Scand 2013;127(3):149–53.
42. Kelemen A., Halasz P. Lacosamide for the prevention of partial onset seizures in epileptic adults. Neuropsychiatr Dis Treat 2010;6: 465–71.
43. Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009;5:757–66.
44. Kellinghaus C. Reversible suicidal ideation fter exposure to lacosamide. Seizure 2013;22(4):318–9.
45. Kobow K., El-Osta A., Blümcke I. The methylation hypothesis of pharmacoresistance in epilepsy. Epilepsia 2013;54 Suppl 2:41–7.
46. Krause L.U., Brodowski K.O., Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav 2011;20(4):725–7.
47. Krauss G., Ben-Menachem E., Mameniskiene R. et al.; SP757 Study Group. Intravenous lacosamide as short-term replacement for oral lacosamide in partialonset seizures. Epilepsia 2010;51(6):951–7.
48. Krauss G.L., Edwards H.B., Lin B. Lacosamide for the treatment of epilepsy. Ann Med 2012;44(7):674–9.
49. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314–9.
50. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8.
51. Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406.
52. Miro J., Toledo M., Santamarina E. et al. Efficacy of intravenous lacosamide as an addon treatment in refractory status epilepticus: a multicentric prospective study. Seizure 2013;22(1):77–9.
53. Niespodziany I., Leclere N., Vandenplas C. et al. Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation. J Neurosci Res 2013;91(3):436–43.
54. Nizam A., Mylavarapu K., Thomas D. et al. Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia 2011;52(10):e153–5.
55. O'Brien T.J., Mosewich R.K., Britton J.W. et al. History and seizure semiology in distinguishing frontal lobe seizures and temporal lobe seizures. Epilepsy Res 2008;82(2–3):177–82.
56. Panayotopoulos С.P. Principles of Therapy in the Epilepsies. In: A Panayotopoulos. Clinical Guide to Epileptic Syndromes and their Treatment. Springer, 2007. Pр. 155–84.
57. Patsalos P.N., Berry D.J. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother 2012;13(5):699–715.
58. Potschka H. Animal and human data: where are our concepts for drug-resistant epilepsy going? Epilepsia 2013;54 Suppl 2: 29–32.
59. Rosenow F., Knake S. Recent and future advances in the treatment of status epilepticus.Ther Adv Neurol Disord 2008;1(1):33–42.
60. Sierra-Marcos A., Bermejo P.E., Manso Calderon R. et al. Lacosamide for epileptic seizures in patients with co-morbidities and unusual presentations of epilepsy. CNS Drugs 2011;25 Suppl 1:17–26.
61. Simoens S. Budget impact analysis of adjunctive therapy with lacosamide for partial-onset epileptic seizures in Belgium. J Med Econ 2011;14(3):299–304.
62. Simoens S. Lacosamide as adjunctive therapy for partial-onset epileptic seizures: a review of the clinical and economic literature. Curr Med Res Opin 2011;27(7):1329–38.
63. Simoens S., De Naeyer L., Dedeken P. Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium. CNS Drugs 2012;26(4):337–50.
64. Uebachs M., Albus C., Opitz T. et al. Loss of β1 accessory Na+ channel subunits causes failure of carbamazepine, but not of lacosamide, in blocking high-frequency firing via differential effects on persistent Na+currents. Epilepsia 2012;53(11):1959–67.
65. Verrotti A., Loiacono G., Olivieri C. et al. Lacosamide in patients with pharmacoresistant epilepsy. Expert Opin Pharmacother 2012;13(14):2065–72.
66. Verrotti A., Loiacono G., Pizzolorusso A. et al. Lacosamide in pediatric and adult patients: comparison of efficacy and safety. Seizure 2013;22(3): 210–6.
67. Villanueva V., Lopez-Gomariz E., Lopez-Trigo J. et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav 2012;23(3):298–304.
68. Vishwanath V.A., Miller L.M. 3rd. What is the right dose of lacosamide in pediatric patients with intractable epilepsy? Epilepsy Behav 2012;23(3):396–7.
69. Wang B., Dawson H., Wang H. et al. Lacosamide improves outcome in a murine model of traumatic brain injury. Neurocrit Care 2013;19(1):125–34.
70. Wilson S.M., Xiong W., Wang Y. et al. Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization. Neuroscience 2012;210:451–66.
Рецензия
Для цитирования:
Пылаева О.А., Мухин К.Ю., Миронов М.Б. Эффективность и переносимость препарата лакосамид (Вимпат) в лечении эпилепсии у взрослых (обзор литературы). Русский журнал детской неврологии. 2014;9(4):59-68. https://doi.org/10.17650/2073-8803-2014-9-4-59-68
For citation:
Pylaeva O.A., Mukhin K.Yu., Mironov M.B. EFFICACY AND TOLERABILITY OF LACOSAMIDE (VIMPAT) FOR TREATMENT OF EPILEPSY IN ADULTS (A REVIEW). Russian Journal of Child Neurology. 2014;9(4):59-68. (In Russ.) https://doi.org/10.17650/2073-8803-2014-9-4-59-68
Просмотров: 3957
Послать статью по эл. почте 